Method for screening compounds inhibiting signal transduction through inflammatory cytokines
First Claim
Patent Images
1. A method of screening for compounds that inhibit production of an inflammatory cytokine, comprising:
- (a) providing a sample comprising a TAK1 and a TAB1;
(b) contacting a test compound with the TAK1 and the TAB1;
(c) detecting binding between the TAK1 and the TAB1; and
(d) selecting a compound that inhibits the binding;
wherein the TAK1 of (a) is selected from the group consisting of (i) a protein comprising amino acids 76 to 303 of SEQ ID NO;
2; and
(ii) a protein that binds to amino acids 437 to 504 of SEQ ID NO;
4 and comprises an amino acid sequence encoded by a DNA sequence that hybridizes with the complement of nucleotides 408 to 1091 of SEQ ID NO;
1 under washing conditions of 42°
C., 5×
SSC, 0.1% sodium dodecyl sulfate, and 50% formamide;
and wherein the TAB1 of (a) is selected from the group consisting of (iii) a protein comprising amino acids 437 to 504 of SEQ ID NO;
4; and
(iv) a protein that binds to amino acids 76 to 303 of SEQ ID NO;
2 and comprises an amino acid sequence encoded by a DNA that hybridizes with the complement of nucleotides 1338 to 1541 of SEQ ID NO;
3 under washing conditions of 42°
C., 5×
SSC, 0.1% sodium dodecyl sulfate, and 50% formamide, wherein the compound inhibits production of an inflammatory cytokine produced in response to lipopolysaccharide (LPS) or IL-1α
.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods of screening for compounds that inhibit signal transduction by inflammatory cytokines. The methods include providing a sample that contains a TAK1 and a TAB1; contacting the sample with a compound; detecting binding between the TAK1 and the TAB1; and selecting the compound if binding between the TAK1 and TAB1 is inhibited in the sample compared to a control.
-
Citations
20 Claims
-
1. A method of screening for compounds that inhibit production of an inflammatory cytokine, comprising:
-
(a) providing a sample comprising a TAK1 and a TAB1;
(b) contacting a test compound with the TAK1 and the TAB1;
(c) detecting binding between the TAK1 and the TAB1; and
(d) selecting a compound that inhibits the binding;
wherein the TAK1 of (a) is selected from the group consisting of (i) a protein comprising amino acids 76 to 303 of SEQ ID NO;
2; and
(ii) a protein that binds to amino acids 437 to 504 of SEQ ID NO;
4 and comprises an amino acid sequence encoded by a DNA sequence that hybridizes with the complement of nucleotides 408 to 1091 of SEQ ID NO;
1 under washing conditions of 42°
C., 5×
SSC, 0.1% sodium dodecyl sulfate, and 50% formamide;
and wherein the TAB1 of (a) is selected from the group consisting of (iii) a protein comprising amino acids 437 to 504 of SEQ ID NO;
4; and
(iv) a protein that binds to amino acids 76 to 303 of SEQ ID NO;
2 and comprises an amino acid sequence encoded by a DNA that hybridizes with the complement of nucleotides 1338 to 1541 of SEQ ID NO;
3 under washing conditions of 42°
C., 5×
SSC, 0.1% sodium dodecyl sulfate, and 50% formamide, wherein the compound inhibits production of an inflammatory cytokine produced in response to lipopolysaccharide (LPS) or IL-1α
. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification